GSK, Crucell to test second-generation malaria vaccine

Jun 8 2011NewsGuard 100/100 Score

GlaxoSmithKline and drug company Crucell, a division of Johnson & Johnson, will collaborate with the PATH Malaria Vaccine Initiative to test a second-generation malaria vaccine "within the next couple of months," Reuters reports. "GSK's first-generation vaccine, known as RTS,S or Mosquirix, is in late-stage development and could reach the market in 2015. ... The new vaccine is an amended version of the current GSK shot that adds an engineered common cold virus developed by Crucell to 'prime' the immune system to get a stronger response," the news service writes (Hirschler, 6/6).

http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Posted in: Disease/Infection News | Pharmaceutical News

Tags: , , , , , , , , ,

Comments (0)

Suggested Reading

Breakthrough discovery could lead to novel malaria vaccines and therapies
Pfizer-BioNTech vaccine provides strong protection against MIS-C in children aged 5–17
Community partnerships lead to more inclusive health care for neurodiverse individuals
WHO grants Emergency Use Listing for LC16m8 mpox vaccine
Study finds artemisinin resistance in African children with severe malaria
New vaccine shows potential in preventing recurrence of triple-negative breast cancer
Early RSV vaccination in pregnancy provides best protection for newborns
Argonne receives $21.7 million to advance cancer and vaccine discoveries

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Innovative vaccine shields livestock from four strains of foot and mouth disease